Heartland

France’s “recreational” cannabis survey • New Mexico governor prioritizes legalization • California eases banking access • & more…

The Cannabis Wire Daily newsletter is sent to C-Wire Plus subscribers every weekday morning at 7 a.m. Excerpts are published here later in the day. Don’t miss the full picture. Subscribe now. In France, parliament members enter next phase of “fact-finding mission” on cannabis. For the past year, dozens of members of parliament in France’s National Assembly have been […]

Published

1 month ago

January 15, 2021

Republished by Plato

The Cannabis Wire Daily newsletter is sent to C-Wire Plus subscribers every weekday morning at 7 a.m. Excerpts are published here later in the day. Don’t miss the full picture. Subscribe now.

In France, parliament members enter next phase of “fact-finding mission” on cannabis.

For the past year, dozens of members of parliament in France’s National Assembly have been on what they call a “fact-finding mission” about cannabis. Until recently, that mission has been focused on medical cannabis, but, now, the group has turned its attention to “recreational cannabis.”

The group released a questionnaire this week in an effort “to better understand the perception of cannabis” among the population and “their vision of the future of public policies in this area.” The questionnaire will be open until the end of February.

California regulators push toward “greater access to financial services” for the cannabis industry.

In September, as Cannabis Wirereported, several cannabis bills were signed by California Governor Gavin Newsom. Among them was Assembly Bill 1525, which, as Newsom wrote at the time, “affirmatively protects certain entities providing financial services to the legal cannabis industry … This bill has the potential to increase the provision of financial services to the legal cannabis industry, and for that reason, I support it.”

This week, regulations to implement this bill have been published (read them here). And, as the regulations come with a proposal for “emergency action,” they are likely to quickly go into effect.

In an email sent to stakeholders, the California Department of Food and Agriculture wrote:

“The proposed regulations create a pathway for licensees to authorize sharing of non-public information with selected financial institutions and provide a mechanism for financial institutions to more readily conduct the federally required reviews of the cannabis business. By reducing the burden of providing financial services to cannabis businesses, more financial institutions may be willing to provide services, thereby reducing the need to keep cash on hand and improving public safety.”

New Mexico governor says cannabis is a priority.

Just as she did in January 2020, New Mexico Gov. Michelle Lujan Grisham included cannabis in her “priorities for the session” ahead of the legislature’s first day on January 19.

As Cannabis Wirereported last January, Grisham called for cannabis legalization during her State of the State address. But even before COVID-19 hit, lawmaker opposition halted the effort.

Now, cannabis is on Grisham’s agenda again. On cannabis, her list of priorities reads:

“Establish an essential new revenue source for the state and employment source for tens of thousands of New Mexicans: Legalizing adult-use recreational cannabis through legislation that protects the state’s medical cannabis program, provides for workplace safety and roadway protections and enforcement and clear labeling of products.”

Colorado: while sales fell after mid-year, a record has been set.

Cannabis sales in the state between January and November exceeded $2 billion. Even though December data has yet to be released, the record for highest annual cannabis sales in the state was $1.75 million in 2019.

While cannabis sales steadily fell in the second half of the year, they hit an unprecedented high in the summer.

Source: https://cannabiswire.com/2021/01/15/frances-recreational-cannabis-survey-%e2%80%a2-new-mexico-governor-prioritizes-legalization-%e2%80%a2-california-eases-banking-access-%e2%80%a2-more/

Up Next

CBD News Roundup: FDA Provides Framework for Future CBD Research

Don't Miss

Virginia Subcommittee on Marijuana Forms to Debate Legalization Bill

Heartland

Charlotte’s Web’s CW Labs Announce New Scientific Collaboration Researching Hemp CBD Efficacy

Harvard Medical School’s Dr. Staci Gruber, Ph.D. is lead investigator BOULDER, Colo., Feb. 24, 2021 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the market leader in hemp CBD wellness products, today announced a long-term scientific collaboration between McLean Hospital, a Harvard Medical School affiliate, and the Company. […]

Published

2 hours ago

February 26, 2021

Republished by Plato

Harvard Medical School’s Dr. Staci Gruber, Ph.D. is lead investigator

BOULDER, Colo., Feb. 24, 2021 /PRNewswire/ – (TSX: CWEB) (OTCQX: CWBHF) Charlotte’s Web Holdings, Inc. (“Charlotte’s Web” or the “Company”), the market leader in hemp CBD wellness products, today announced a long-term scientific collaboration between McLean Hospital, a Harvard Medical School affiliate, and the Company. Funding and product support are provided by the CW Labs division of Charlotte’s Web Inc.

Two distinct clinical trials will be overseen by lead researcher/investigator Dr. Staci A. Gruber, Ph. D, Associate Professor of Psychiatry at Harvard Medical School and Director of the MIND program at McLean Hospital in Belmont, Mass. These two studies will investigate the efficacy of a custom-formulated, hemp-derived high-CBD product. Clinical trial results are to be published in 2022. Dr. Gruber is also conducting a number of other studies, including a longitudinal observational study of Veterans who use a Charlotte’s Web product.

Dr. Gruber’s Marijuana Investigations for Neuroscientific Discovery (MIND) Program, established in 2014, is the first of its kind, and is dedicated to studying the long-term impact of cannabis and cannabinoids for medical and adult use which utilizes various clinical and cognitive tools as well as multimodal neuroimaging techniques.

We are honored to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials. Charlotte’s Web remains dedicated to supporting third-party research on hemp CBD investigated by some of the country’s top scientists.

Tim Orr, President of Charlotte’s Web’s CW Labs divison

For More Information About the MIND Program: https://www.drstacigruber.com/

About the MIND Program:

In 2014 Dr. Staci Gruber launched the Marijuana Investigations for Neuroscientific Discovery (MIND) program at Mclean Hospital, a Harvard Medical School affiliate. The MIND program is the first program of its kind designed to clarify the specific effects of medical cannabis use and is designed to support a wide range of study designs that generate ecologically valid, empirically sound data to close the gap between policy and science. MIND utilizes valid, robust research models and supports numerous projects designed to address the impact of medical cannabis on important variables such as cognition, brain structure and function, mood, conventional medication use, quality of life, pain, sleep, and other health-related measures. Through observational longitudinal investigations, survey studies, and clinical trials of custom-formulated cannabinoid products, MIND aims to examine the unique and synergistic effects of cannabis and its constituents to determine the efficacy of cannabinoids for specific conditions and diseases and to clarify the overall impact of cannabinoid-based treatments on physical and mental health. MIND is poised to improve patients’ overall wellbeing by striving to harness the therapeutic potential while minimizing harms of cannabinoid-based treatment.

About Charlotte’s Web and its CW Labs Division

Charlotte’s Web Labs (“CW Labs”) is the research and development division of Charlotte’s Web, advancing science around hemp-derived phytocannabinoids, terpenes and flavonoid compounds. CW Labs is headquartered at the Hauptmann Woodward Research Institute on the campus of the University at Buffalo’s Jacobs School of Medicine and The Center for Integrated Global Biomedical Sciences, and is part of the State University of New York (SUNY) network of 64 national and international research and medical institutions.

About Charlotte’s Web Holdings, Inc.

Charlotte’s Web Holdings, Inc., a Certified B Corporation headquartered in Boulder, Colorado, is the market leader in the production and distribution of innovative hemp-derived cannabidiol (“CBD”) wellness products under a family of brands which includes Charlotte’s Web™, CBD Medic™, CBD Clinic™, and Harmony Hemp. The Company’s premium quality products start with proprietary hemp genetics that are 100-percent American farm grown and manufactured into whole-plant hemp extracts containing a full spectrum of naturally occurring phytocannabinoids including CBD, CBC, CBG, terpenes, flavonoids and other beneficial hemp compounds. Charlotte’s Web product categories include CBD oil tinctures (liquid products), CBD gummies (sleep, stress, inflammation recovery), CBD capsules,CBD topical creams and lotions, as well as CBD pet products for dogs. Charlotte’s Web is the number one CBD brand in the USA and distributed through more than 22,000 retail locations, select distributors and online through the Company’s website at www.CharlottesWeb.com.

Charlotte’s Web was founded by the Stanley Brothers with a mission to unleash the healing powers of botanicals through compassion and science, benefiting the planet and all who live upon it. Charlotte’s Web is a socially and environmentally conscious company and is committed to using business as a force for good and a catalyst for innovation. The Company weighs sound business decisions with consideration for how its efforts affect employees, customers, the environment, and diverse communities. The rate the Company pays for agricultural products reflects a fair and sustainable rate driving higher quality yield, encouraging regenerative farming practices, and supporting U.S. farming communities. Management believes that its socially oriented and environmentally responsible actions have a positive impact on its customers, suppliers, employees, and stakeholders. Charlotte’s Web donates a portion of its pre-tax earnings to charitable organizations.

Subscribe to Charlotte’s Web investor news.

Original press release

Published by NCV Newswire

The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Source: https://www.newcannabisventures.com/charlottes-webs-cw-labs-announce-new-scientific-collaboration-researching-hemp-cbd-efficacy/

Heartland

Is cbd oil worth it’s price or should I stick to flower?

Published

3 hours ago

February 26, 2021

Republished by Plato

Tldr- bud or bottle?

So, I have been smoking high quality outdoor/greenhouse CBD/CBG from Beleafer. Now, my problem is, I dont really feel effects anymore, like, I use my cbd flower to mix with normal high potency weed and it works great, I feel less paranoia, thats all well, but as I say, if I smoke cbd alone its really like im doing something for nothing, this could be because I only get ounces from Beleafer as they last me months, but I probably have a tolerance with each strain by the time I finish it.

My issue is this. I need relief badly(psychological and physical issues), and when I used a high quality cbd oil, it helped, at low 5% dosage, but it was a pretty penny.

When I look at the cbd I want to get now its 129€ for 40% or I can get 2x 20% for the same price. They are 10ml bottles.

HOWEVER, I can get an ounce of indoor cbd for a similar slightly less price, only issue is shipping times, AND – IS SHIPPING OF CBD FLOWER STILL POSSIBLE OR TOTALLY STOPPED? This is probably my only issue now thinking about it.

I digress, basically I can get good strong cbd to smoke for months, or I can get a bottle of oil that could last a month depending if it works and if I stick to dosages instead of just start doing drops all day.

I enjoy cbd and it does work, I just dont know if I have a high tolerance now and it means I have to only fork out on high potency stuff.

Oh, the point of this post is that with smoking cbd, I cant say I feel any health benefits like pain relief etc, however when I used oil I think it definitely helped in more ways than just one (relaxed after a bong)

What would you do in this case? Bud or bottle?

Oh im in France so this makes it difficult with certain brands that dont ship intl.

Source: https://www.reddit.com/r/CBD/comments/lt0hvr/is_cbd_oil_worth_its_price_or_should_i_stick_to/